Skip to content

Axogen AXGN Accounts Receivable, Credit Loss Expense (Reversal)

Accounts Receivable, Credit Loss Expense (Reversal) at other companies

LeMaitre Vascular logo
LeMaitre VascularLMAT
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$61.5M+26.6%
Gross profit$46.2M+32.2%
Operating income-$2.8M-70.5%
Net income-$19.6M-411%
EPS (diluted)-$0.38-375%

Balance sheet

See full
Cash & equivalents$84.7M+251%
Total debt$20.6M-69.8%
Total equity$244.8M+132%
Total assets$289.5M+47.6%

Cash flow

See full
Operating cash flow$1.6M+112%
CapEx$2.8M+989%
Free cash flow-$1.2M+90.9%

Valuation

See full
Market cap$2.26B+110%

Profitability

See full
Gross margin75%+0.8pp
Operating margin-3.8%
Net margin-13.2%-22.8pp
FCF margin-12.9%-3.8pp

Returns & leverage

See full
Return on equity-18%-70.5pp
Debt / equity0.1×-0.6×
Current ratio7.1×+2.8×

Where this comes from

Reported directly by Axogen in its filing.

Tagged under the XBRL concept us-gaap:ProvisionForDoubtfulAccounts.

The official record: Axogen’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Axogen's accounts receivable, credit loss expense (reversal).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Axogen's accounts receivable, credit loss expense (reversal)?
Axogen (AXGN) reported accounts receivable, credit loss expense (reversal) of -$120K in Q1 2026.
How has Axogen's accounts receivable, credit loss expense (reversal) changed year-over-year?
Axogen's accounts receivable, credit loss expense (reversal) decreased by 164.2% year-over-year, from $187K to -$120K.
What is the long-term trend for Axogen's accounts receivable, credit loss expense (reversal)?
Over 2 years (2022 to 2025), Axogen's accounts receivable, credit loss expense (reversal) has grown at a -16.4% compound annual growth rate (CAGR), from $612K to $428K.